• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过 QuPath 分析评估未经治疗的上消化道癌内镜活检中的肿瘤区域浸润和细胞计数:对预测生物标志物检测的影响。

Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing.

机构信息

Institute of Pathology, University Hospital Cologne, Medical Faculty, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Medical Faculty, University of Cologne, Cologne, Germany.

出版信息

Sci Rep. 2023 Oct 16;13(1):17580. doi: 10.1038/s41598-023-43903-3.

DOI:10.1038/s41598-023-43903-3
PMID:37845307
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10579338/
Abstract

Guidelines regulate how many (tumour-bearing) tissue particles should be sampled during gastric cancer biopsy to obtain representative results in predictive biomarker testing. Little is known about how well these guidelines are applied, how the number of tissue particles correlates with the actual tumour-infiltrated area and how many absolute tumour cells are captured. The study included endoscopic biopsies of untreated carcinomas of the upper gastrointestinal (GI)-tract during the 2016-2020 review period. Archival (H&E)-stained histological sections were digitised and the tumour areas were manually annotated. The tumour-bearing tissue area and absolute carcinoma cell count per case were determined by image analysis and compared with a reference primary surgical specimen. Biopsies from 253 patients were analysed. The following mean values were determined: (a) tumour tissue particle number: 6.5 (range: 1-25, standard deviation (SD) = 3.33), (b) number of tumour-bearing tissue particles: 4.7 (range: 1-20, SD = 2.80), (c) tumour-infiltrated area: 7.5 mm (range: 0.18-59.46 mm, SD = 6.67 mm), (d) absolute tumour cell count: 13,492 (range: 193-92,834, SD = 14,185) and (e) tumour cell count in a primary surgical specimen (tumour size: 6.7 cm): 105,200,176. The guideline-recommended tissue particle count of 10 was not achieved in 208 patients (82.2%) and the required tumour-bearing tissue particle count of 5 was not achieved in 133 patients (52.6%). Tissue particle count, tumour-infiltrated area and tumour cell count were only weakly correlated. Most cases featured an infiltrated area ≥ 4.5 mm (156, 61.7%). Cases with more tissue particles showed only a moderate increase in infiltrated area and tumour cells compared to cases with fewer particles. Biopsies are often used to determine predictive biomarkers, particularly Her2/neu and PD-L1. Diagnostic standards to ensure representative material have been suggested in guidelines to reduce false-negative predictions. However, the real-world practice seems to substantially deviate from recommended standards. To the best of our knowledge, this is the first systematic study describing the relationships between endoscopic tissue fragment number, actual infiltrated tumour area and carcinoma cell number. The data question the tissue particle number as a quality assessment parameter. We advocate histopathological reports indicating on which basis statements on therapy-relevant biomarkers were made. Digital pathology has the potential to objectively quantify the tissue for documentation, quality assessment and future clinical studies.

摘要

指南规定了在胃癌活检中应采集多少(含肿瘤)组织颗粒,以在预测性生物标志物检测中获得代表性结果。对于这些指南的应用程度、组织颗粒数量与实际肿瘤浸润面积的相关性以及捕获的绝对肿瘤细胞数量知之甚少。该研究纳入了 2016 年至 2020 年审查期间未经治疗的上消化道(GI)癌的内镜活检。对存档的(苏木精-伊红(H&E))染色组织学切片进行数字化,并手动标注肿瘤区域。通过图像分析确定每个病例的含肿瘤组织面积和绝对癌细计数,并与参考原发性手术标本进行比较。对 253 例患者的活检进行了分析。确定了以下平均值:(a)肿瘤组织颗粒数:6.5(范围:1-25,标准差(SD)=3.33),(b)含肿瘤组织颗粒数:4.7(范围:1-20,SD=2.80),(c)肿瘤浸润面积:7.5mm(范围:0.18-59.46mm,SD=6.67mm),(d)绝对肿瘤细胞计数:13492(范围:193-92834,SD=14185)和(e)原发性手术标本中的肿瘤细胞计数(肿瘤大小:6.7cm):105200176。在 208 例患者(82.2%)中未达到指南推荐的 10 个组织颗粒计数,在 133 例患者(52.6%)中未达到 5 个含肿瘤组织颗粒计数。组织颗粒计数、肿瘤浸润面积和肿瘤细胞计数仅呈弱相关。大多数病例的浸润面积≥4.5mm(156 例,61.7%)。与颗粒较少的病例相比,颗粒较多的病例的浸润面积和肿瘤细胞仅略有增加。活检常用于确定预测性生物标志物,特别是 Her2/neu 和 PD-L1。为了减少假阴性预测,指南中提出了确保代表性材料的诊断标准。然而,实际情况似乎与推荐标准有很大偏差。据我们所知,这是第一项描述内镜组织碎片数量、实际浸润肿瘤面积和癌细数量之间关系的系统研究。该数据对组织颗粒数量作为质量评估参数提出了质疑。我们主张在病理报告中注明做出与治疗相关生物标志物相关声明的依据。数字病理学具有客观量化组织的潜力,可用于记录、质量评估和未来的临床研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/21d531220569/41598_2023_43903_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/e75bf5ec4155/41598_2023_43903_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/75113e3e5458/41598_2023_43903_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/79f9678c7c83/41598_2023_43903_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/21d531220569/41598_2023_43903_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/e75bf5ec4155/41598_2023_43903_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/75113e3e5458/41598_2023_43903_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/79f9678c7c83/41598_2023_43903_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f75/10579338/21d531220569/41598_2023_43903_Fig4_HTML.jpg

相似文献

1
Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing.通过 QuPath 分析评估未经治疗的上消化道癌内镜活检中的肿瘤区域浸润和细胞计数:对预测生物标志物检测的影响。
Sci Rep. 2023 Oct 16;13(1):17580. doi: 10.1038/s41598-023-43903-3.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Upper GI biopsies for adenocarcinoma - how many biopsies should endoscopists take?上消化道腺癌活检——内镜医生应该取多少活检?
Histopathology. 2019 May;74(6):959-963. doi: 10.1111/his.13816. Epub 2019 Apr 1.
4
Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.免疫组化检测内镜下胃活检组织中 PTEN、HER2/neu 和 Ki-67 的表达及其与组织学分型和一年生存率的关系。
Indian J Pathol Microbiol. 2022 Jan-Mar;65(1):29-34. doi: 10.4103/IJPM.IJPM_299_20.
5
Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.使用内镜超声和腹腔镜超声对上消化道癌患者进行治疗前评估。
Dan Med J. 2012 Dec;59(12):B4568.
6
Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.胃肠道免疫相关不良反应:上消化道活检的诊断效用。
Histopathology. 2020 Jan;76(2):233-243. doi: 10.1111/his.13963. Epub 2019 Nov 13.
7
Gastroscopic biopsy: reliability of histological diagnosis with special reference to the single biopsy.胃镜活检:组织学诊断的可靠性,特别提及单次活检
Scand J Gastroenterol. 1975;10(5):453-8.
8
A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.24 例累及胃肠道的系统性肥大细胞增多症的临床病理研究及肠易激综合征和无症状患者的黏膜肥大细胞密度评估。
Am J Surg Pathol. 2014 Jun;38(6):832-43. doi: 10.1097/PAS.0000000000000190.
9
Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.在真实世界中,针对活检技术和新辅助治疗,研究肺癌患者诊断性活检和手术标本中肿瘤细胞 PD-L1 表达的相关性。
J Cancer Res Clin Oncol. 2023 May;149(5):1747-1754. doi: 10.1007/s00432-022-04080-4. Epub 2022 Jun 16.
10
Optimized PD-L1 scoring of gastric cancer.优化胃癌 PD-L1 评分。
Gastric Cancer. 2021 Sep;24(5):1115-1122. doi: 10.1007/s10120-021-01195-4. Epub 2021 May 5.

引用本文的文献

1
Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.CSPG4在黑色素瘤和痣中的诊断潜力增强:与PRAME、CDC7和Ki67的比较研究
J Pathol. 2025 Jul 23. doi: 10.1002/path.6450.
2
Amphibian cellular immune response to chytridiomycosis at metamorphic climax.变态高峰期两栖动物对蛙壶菌病的细胞免疫反应。
Immunol Res. 2025 Jan 30;73(1):44. doi: 10.1007/s12026-025-09599-5.

本文引用的文献

1
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌(CheckMate 649):一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
2
Optimized PD-L1 scoring of gastric cancer.优化胃癌 PD-L1 评分。
Gastric Cancer. 2021 Sep;24(5):1115-1122. doi: 10.1007/s10120-021-01195-4. Epub 2021 May 5.
3
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
贝伐珠单抗联合改良 FOLFOX6 方案治疗晚期 FGFR2 阳性胃食管结合部腺癌的 FIGHT Ⅲ期临床研究设计
Future Oncol. 2019 Jun;15(18):2073-2082. doi: 10.2217/fon-2019-0141. Epub 2019 May 16.
4
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.IMAB362(Zolbetuximab)治疗晚期胃癌和胃食管结合部癌的 I 期剂量递增研究。
Eur J Cancer. 2018 Sep;100:17-26. doi: 10.1016/j.ejca.2018.05.007. Epub 2018 Jun 21.
5
QuPath: Open source software for digital pathology image analysis.QuPath:用于数字病理学图像分析的开源软件。
Sci Rep. 2017 Dec 4;7(1):16878. doi: 10.1038/s41598-017-17204-5.
6
HER2 testing in gastric cancer: results of a German expert meeting.胃癌中的HER2检测:德国专家会议结果
J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11.
7
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014.韩国癌症统计数据:2014年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2017 Apr;49(2):292-305. doi: 10.4143/crt.2017.118. Epub 2017 Mar 9.
8
Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.胃癌中HER2、FGFR2、cMET和ATM的肿瘤内异质性:通过创新的病理学和统计分析优化个性化医疗
PLoS One. 2015 Nov 20;10(11):e0143207. doi: 10.1371/journal.pone.0143207. eCollection 2015.
9
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.来自ToGA研究的HER2筛查数据:针对胃及胃食管交界癌中的HER2靶点
Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20.
10
HER2 testing in gastric cancer: a practical approach.胃肿瘤 HER2 检测:实用方法。
Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6.